Tourmaline Bio Stock (NASDAQ:TRML)
Previous Close
$47.60
52W Range
$11.56 - $47.70
50D Avg
$23.40
200D Avg
$18.83
Market Cap
$1.22B
Avg Vol (3M)
$655.60K
Beta
2.06
Div Yield
-
TRML Company Profile
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.